Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
about
Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patientsComparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyThe antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in SpainEffect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley ratsFoxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein MImpact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?Prevalence and comorbidities of known diabetes in northeastern Italy.Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Markers of cardiovascular risk in postmenopausal women with type 2 diabetes are improved by the daily consumption of almonds or sunflower kernels: a feeding study.Suppression of low-density lipoprotein oxidation, vascular smooth muscle cell proliferation and migration by a herbal extract of Radix Astragali, Radix Codonopsis and Cortex LyciiRole of SN1 lipases on plasma lipids in metabolic syndrome and obesityTreatment of dyslipidemia in patients with type 2 diabetes.The association between improved quality diabetes indicators, health outcomes and costs: towards constructing a "business case" for quality of diabetes care--a time series study.Berries: emerging impact on cardiovascular health.Male gender, increased blood viscosity, body mass index and triglyceride levels are independently associated with systemic relative hypertension in sickle cell anemia.Paederia foetida Linn. leaf extract: an antihyperlipidemic, antihyperglycaemic and antioxidant activityType 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function[Diagnosis and prevalence of metabolic syndrome in diabetics followed in a context of limited resources: the case of Burkina Faso]Hypoglycemic and hypolipidemic activities of aqueous extract of flowers from Nycantus arbor-tristis L. in male miceAnti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients.Gestational diabetes mellitus is associated with increased leukocyte peroxisome proliferator-activated receptor γ expression.Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease.Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients.Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.Insulin-associated weight gain in diabetes--causes, effects and coping strategies.p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy.Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men.Prevalence of Type 2 Diabetes Mellitus among Urban Sikh Population of Amritsar.Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans.Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans.Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics.Hyperlipidemia: a new therapeutic target for diabetic neuropathy.Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (prExtended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicThe eSS rat, a nonobese model of disordered glucose and lipid metabolism and fatty liver.
P2860
Q24634840-026D68FC-B213-4885-91A4-4BD1C3A7BD27Q24814804-348EFDF9-C57F-48CB-A1BC-B538A20C58D3Q24816874-83ABE97E-E8DC-49CD-B1A7-8CFD7293BA41Q28222880-D6DCB240-685C-41EE-8E18-61CB4FA817CCQ28536348-C478A9A3-540D-4BF4-95C4-E0E93D265F90Q28594461-C9773701-1871-4C59-B1BE-2501E4D9E115Q30234825-01B2DE70-C331-414A-8B1B-E3EEB315438FQ33607611-E5B0D648-7AE9-475D-94F5-DB2273C73BDEQ33706621-00F48270-91B7-4050-B16D-1098A0D4F3E0Q33710216-F0E829B4-F2E6-405C-B90E-D73C5E353868Q33879755-D622C6FE-94BC-42A8-926E-ECDEE682ABFEQ33925409-FEF02EAA-BC70-4979-BC84-3997EDD24E68Q34499472-92F0FE1D-A5B7-4B8D-8A6E-24D8A726960FQ34695176-F91131F7-AA92-40B1-881E-85FFE4ACCAE3Q34745687-95B1FAC5-8905-4851-B4C4-75C358BD4CBEQ34778805-1D31AF2C-9B14-4F98-AC5C-C7EF01B54028Q35101849-CCA62D1F-2DAA-413B-A36A-55795031B350Q35131581-11D71224-49F7-45CD-973A-6E4E4EBC3E9CQ35532569-286FAC64-3D97-466E-B30F-BB79519422C4Q35749271-D468D48B-7029-4A84-B02B-064F2683ED10Q35960732-27AC6F85-27DF-430D-B1EE-1C8C75480C3FQ35992073-CAA70D03-B09B-4243-B764-E626ED933234Q36362707-6E217487-168D-48D4-9151-D5B8028E5DA6Q36449733-7DC79924-8DBC-410F-80A0-9E8B65032159Q36727852-3D2C8666-CECF-4DEA-8688-0D5E05FCB144Q36966063-33A9417A-67C1-4B35-981D-26F4CA4F34F1Q36966075-ADA1F82C-6F23-4A81-9FB2-DEACF95C9AA2Q37063929-E41C5807-2E20-470B-AB4C-70232BF096CFQ37108070-260B0153-F9F9-4D5A-A1A5-2922C026BD6EQ37419776-AF59E347-95AE-4EA2-AB89-7FD0A0321504Q37600104-E56104CC-BB05-4E1F-97C7-FBA89A861373Q37602518-DD368DCE-1A19-4AEF-B511-A3EF8C26E2CCQ37645663-3AF21B08-6612-4D78-A9A1-361A0EDEE5C7Q37659233-2A1514F5-19F8-46E8-9229-1A46EC27DA4BQ37660996-4EE66877-3FAA-4444-8A32-FE47B872150EQ38011204-894FB1ED-E21E-44B3-9862-38AD10937F13Q38219490-82DFE4F7-E1C1-4293-9BF8-A87B4C7E17ADQ38282408-F1B985D9-36F9-4768-BA58-374CB83055A3Q38382774-39E8F16B-1D01-44D8-866A-C5BC59E6E9C4Q39860522-D7452785-AE80-4152-83CF-3DEB065B843C
P2860
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@ast
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@en
type
label
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@ast
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@en
prefLabel
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@ast
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@en
P2860
P1476
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
@en
P2093
Andrew J Krentz
P2860
P304
P356
10.1046/J.1462-8902.2003.0310.X
P478
P577
2003-11-01T00:00:00Z